Anthera Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, the company's loss from operations was $8,659,000 compared to $14,281,000 a year ago. Net income applicable to common stockholders was $313,000 or $0.03 per basic and diluted share compared to loss of $14,334,000 or $2.79 per basic and diluted share a year ago. For the six months, the company's loss from operations was $19,263,000 compared to $25,998,000 a year ago. Net loss applicable to common stockholders was $13,397,000 or $1.58 per basic and diluted share compared to $26,060,000 or $5.14 per basic and diluted share a year ago.